Market Cap | 1.64B | P/E | 34.75 | EPS this Y | - | Ern Qtrly Grth | -51.50% |
Income | 707.42M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -24.00% |
Sales | 6.08B | PEG | - | EPS past 5Y | - | 200D Avg Chg | -30.00% |
Dividend | N/A | Price/Book | 0.17 | EPS next 5Y | - | 52W High Chg | -64.00% |
Recommedations | - | Quick Ratio | 0.92 | Shares Outstanding | 235.63M | 52W Low Chg | - |
Insider Own | - | ROA | 5.99% | Shares Float | 78.97M | Beta | 1.54 |
Inst Own | 0.02% | ROE | 7.03% | Shares Shorted/Prior | -/- | Price | 6.95 |
Gross Margin | 66.08% | Profit Margin | 11.63% | Avg. Volume | 9,418 | Target Price | - |
Oper. Margin | 18.63% | Earnings Date | Nov 15 | Volume | 8,654 | Change | -0.57% |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.